Regulus Achieves All Research Milestones in Collaboration with Biogen to Identify microRNA Biomarkers for Multiple Sclerosis

October 28, 2015

LA JOLLA, Calif., Oct. 28, 2015 /PRNewswire/ — Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that it has earned a fourth milestone payment in its collaboration with Biogen (NASDAQ: BIIB) related to progress in the companies’ research collaboration to identify microRNAs as biomarkers for multiple […]

Read the full article →

Abcam Webinar: Developing Durable miRNA Biomarker Technologies for Microbial Carcinogenesis in Resource Poor Settings

October 28, 2015

Abcam is hosting a free webinar titled “Developing durable miRNA biomarker technologies for microbial carcinogenesis in resource poor settings”. Live Webinar Details Wednesday, November 4, 2015 16:00-17:00 CET/ 15:00-16:00 GMT/ 10:00-11:00 EST/ 07:00-08:00 PST Register here: http://www.abcam.com/mirnaprofilingwebinar Webinar Summary: Currently, more than half of the global cancer burden occurs in low-and middle-income countries, with 40% […]

Read the full article →

15 Novel Kits for the Isolation of High-Quality Circulating Nucleic Acids from Blood, Plasma, Serum and Urine

September 29, 2015

THOROLD, ON, Sept. 28, 2015 /PRNewswire/ – Norgen Biotek Corp., an innovative privately held Canadian biotechnology company focusing primarily on advancing powerful tools for nucleic acids (NA) and protein purification, today announced the launch of over 15 novel kits for the fast and simple isolation of NA from blood, plasma/serum and urine, including cell-free-circulating (cfc)RNA, cfcDNA […]

Read the full article →

Call for Papers: Special Issue – MicroRNA Regulation

September 28, 2015

The International Journal of Molecular Sciences (Impact Factor 2.862) is working on a Special Issue ” MicroRNA Regulation” and is calling for submissions. Deadline for manuscript submissions is 31 March 2016. For more information please read the letter of the special issue editor: Dear Colleagues, MicroRNA is a short non-coding RNA whose primary function is […]

Read the full article →

MicroRNA Prediction and Validation In Order to Understand Racial Health Disparities in Prostate Cancer

July 15, 2015

It is well documented that African American (AA) men have higher incidence and mortality in cancers of the prostate. Additionally, these cancers tend to be more aggressive when compared with European American (EA) men. Investigators at George Washington University, Duke University, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, and the National Institute […]

Read the full article →

Encouraging Results from MesomiR-1 Phase 1 Trial in Late Stage Mesothelioma patients

June 15, 2015

Dramatic Response with Novel microRNA Replacement Therapy in Malignant Pleural Mesothelioma Published in the American Journal of Respiratory and Critical Care Medicine NEW YORK and SYDNEY, June 15, 2015 /PRNewswire/ — EnGeneIC Ltd, an emerging biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutics, announced today that, together with the Asbestos Diseases […]

Read the full article →

3D Animation of MicroRNA biogenesis and functions

June 5, 2015

Ever had trouble explaining what you are doing? Now there is help… If you haven’t seen it on our Facebook page yet: Thanks go to Katharina Petsche who created a 3D medical animation about microRNAs‬ for her master graduation project. Very Cool!

Read the full article →

Regulus Initiates Phase I Clinical Study of RG-012, a microRNA Therapeutic in Development for the Treatment of Alport Syndrome

June 4, 2015

Achieves Key ‘Clinical Map Initiative’ Goal for 2015 and Advances Orphan Disease Efforts LA JOLLA, Calif., June 4, 2015 /PRNewswire/ — Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that dosing has begun in a first-in-human Phase I clinical study of RG-012, a single stranded, chemically […]

Read the full article →

Workshop: microRNA Research & Immunology

May 7, 2015

If you are traveling to New Orleans to attend IMMUNOLOGY 2015 you might be interested in the following workshop next Monday, May 11th: Recent Work & Current Methods in Immunology microRNA Research May 11, 2015 – 11:15 AM-12:00 PM – Exhibit Hall Workshop Room #1 There is now strong evidence suggesting that miRNA signaling plays a […]

Read the full article →

Mirna Therapeutics Secures $41.8 Million Series D Financing to Advance Oncology MicroRNA Pipeline

April 30, 2015

Series D is Mirna’s Largest Financing to Date With Ten Institutional and Strategic Investors AUSTIN, TX–(Marketwired – April 30, 2015) – Mirna Therapeutics (Mirna), a private, clinical-stage biopharmaceutical and immuno-oncology company focused on the development of microRNA-based cancer therapeutics, today announced the completion of a $41.8 million Series D financing. The company’s second institutional financing was […]

Read the full article →